A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
- 1 June 1993
- Vol. 71 (11), 3520-3525
- https://doi.org/10.1002/1097-0142(19930601)71:11<3520::aid-cncr2820711110>3.0.co;2-a
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Sequential chemoimmunotherapy in the treatment of metastatic melanoma.Journal of Clinical Oncology, 1992
- Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.Journal of Clinical Oncology, 1991
- A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.Journal of Clinical Oncology, 1991
- Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated With Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group TrialJNCI Journal of the National Cancer Institute, 1990
- A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanomaCancer, 1990
- The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanomaCancer, 1989
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987